Home » Venture Capital » Current Portfolio

Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Descriptionsort icon Status Initial Date
<a href="/venture-capital/all-companies/receptos-inc">Receptos, Inc.</a> Developing therapeutic candidates for the treatment of immune and metabolic diseases. Public 2009 View Profile
<a href="/venture-capital/all-companies/celexion-llc">Celexion LLC</a> Developing powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. Private 2009 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Developing innovative technology for the low-cost conversion of abundant biomass. Private 2006 View Profile
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing ground-breaking tools in high definition diagnostics. Private 2007 View Profile
<a href="/venture-capital/all-companies/wikicell-designs">WikiCell Designs</a> Developing deliciously edible forms of packaging that enclose food or drinks in ways similar to how nature protects foods. Private 2012 View Profile
<a href="/venture-capital/all-companies/tangent-medical-technologies-inc">Tangent Medical Technologies Inc.</a> Developing and commercializing IV therapy products. Private 2011 View Profile
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Private 2008 View Profile
<a href="/venture-capital/all-companies/seventh-sense-biosystems-inc">Seventh Sense Biosystems, Inc.</a> Developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. Private 2007 View Profile
<a href="/venture-capital/all-companies/medidametrics-inc">MedidaMETRICS, Inc.</a> Developing activity-based costing systems for healthcare providers. Private 2010 View Profile
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing a pipeline of innovative treatments for bladder diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Developing a new class of highly selective targeted and programmable therapeutics called Accurins™. Private 2007 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/tetraphase-pharmaceuticals-inc">Tetraphase Pharmaceuticals, Inc.</a> Creating novel antibiotics for serious and life-threatening multi-drug resistant infections. Public 2006 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Creating novel and differentiated biotherapeutics: first-of-a-kind protein-based drugs. Private 2008 View Profile
<a href="/venture-capital/all-companies/midori-renewables-inc">Midori Renewables Inc.</a> Commercializing chemical catalysts for upgrading waste biomass to fuels, chemicals, and materials. Private 2010 View Profile
<a href="/venture-capital/all-companies/novomer-inc">Novomer, Inc.</a> Commercializing a family of low-cost, high-performance, sustainable polymers and other chemicals. Private 2007 View Profile
<a href="/venture-capital/all-companies/joule-unlimited-inc">Joule Unlimited, Inc.</a> Capitalizing on the global abundance of waste CO2 to economically produce renewable fuels and chemicals. Private 2007 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Private 2006 View Profile
<a href="/venture-capital/all-companies/avedro-inc">Avedro, Inc.</a> Advancing the science and technology of corneal crosslinking. Private 2009 View Profile